Risk factors for rebleeding and mortality from acute upper gastrointestinal hemorrhage in human immunodeficiency virus infection.
In the general population, acute upper gastrointestinal hemorrhage (UGIH) is a common problem that results in significant morbidity and mortality. The aim of this study was to determine the etiology, clinical outcome, and risk factors for rebleeding and mortality in a large cohort of human immunodeficiency virus (HIV)-infected patients with acute UGIH. We reviewed the medical records of consecutive HIV-infected patients with acute UGIH who were referred for an endoscopic evaluation from January 1992 through January 1997 at Bellevue Hospital Center. During the 5-yr study period, 297 HIV-infected patients with acute UGIH were evaluated by endoscopy. Gastroduodenal ulcers (25.6%), esophageal ulcers (21.5%), and Kaposi's sarcoma (19.2%) were the three most common causes of acute UGIH. Fifteen percent of patients rebled within 30 days and independent predictors of rebleeding included a CD4 count of <200 cells/mm3, inpatient status, a hemoglobin of <8 g/dl, major stigmata of hemorrhage, and lymphoma. The 30-day mortality from UGIH was 11.4% and a hemoglobin of <8 g/dl, a platelet count of <100,000/mm3, major stigmata of hemorrhage, rebleeding within 30 days, and lymphoma were independent predictors of mortality. The introduction of protease inhibitors in December 1995 resulted in a reduction in 30-day mortality from 13.5% to 4.4% (p = 0.04) without affecting the etiology of UGIH or the incidence of rebleeding. Acute UGIH in HIV-infected patients is most commonly due to gastroduodenal ulcers, esophageal ulcers, and Kaposi's sarcoma. In this patient population, the introduction of protease inhibitors has had a positive impact on the outcome of UGIH.